Pneumococcal Vaccines

Ron Dagan; Shalom Ben-Shimol

doi:10.1007/978-3-030-77173-7_21

Pneumococcal Vaccines

Ron Dagan, Shalom Ben-Shimol

Faculty of Health Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Pediatric vaccination against invasive pneumococcal disease (IPD) made a breakthrough in 2000 when a 7-valent pneumococcal conjugate vaccine was licensed. Subsequently, the spectrum was to introduce 10- and 13-valent conjugate vaccines PCV10 and PCV 13, which cover most of the IPD serotypes in children in developed countries. Those vaccines are highly effective against IPD caused by the vaccine serotypes, and are now part of infant immunization programs in most European countries and elsewhere. While effective against IPD, the conjugate vaccines have much less efficacy against pneumococcal pneumonia which remains a major cause of childhood mortality globally.

Original language	English
Title of host publication	Pediatric Vaccines and Vaccinations
Subtitle of host publication	A European Textbook: Second Edition
Publisher	Springer International Publishing
Pages	223-247
Number of pages	25
ISBN (Electronic)	9783030771737
ISBN (Print)	9783030771720
DOIs	https://doi.org/10.1007/978-3-030-77173-7_21
State	Published - 1 Jan 2021

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology
General Pharmacology, Toxicology and Pharmaceutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-030-77173-7_21

Cite this

@inbook{06c5947911e34a2abcd4a8ca0b5dc37e,

title = "Pneumococcal Vaccines",

abstract = "Pediatric vaccination against invasive pneumococcal disease (IPD) made a breakthrough in 2000 when a 7-valent pneumococcal conjugate vaccine was licensed. Subsequently, the spectrum was to introduce 10- and 13-valent conjugate vaccines PCV10 and PCV 13, which cover most of the IPD serotypes in children in developed countries. Those vaccines are highly effective against IPD caused by the vaccine serotypes, and are now part of infant immunization programs in most European countries and elsewhere. While effective against IPD, the conjugate vaccines have much less efficacy against pneumococcal pneumonia which remains a major cause of childhood mortality globally.",

author = "Ron Dagan and Shalom Ben-Shimol",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021.",

year = "2021",

month = jan,

day = "1",

doi = "10.1007/978-3-030-77173-7_21",

language = "English",

isbn = "9783030771720",

pages = "223--247",

booktitle = "Pediatric Vaccines and Vaccinations",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Pneumococcal Vaccines

AU - Dagan, Ron

AU - Ben-Shimol, Shalom

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021.

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Pediatric vaccination against invasive pneumococcal disease (IPD) made a breakthrough in 2000 when a 7-valent pneumococcal conjugate vaccine was licensed. Subsequently, the spectrum was to introduce 10- and 13-valent conjugate vaccines PCV10 and PCV 13, which cover most of the IPD serotypes in children in developed countries. Those vaccines are highly effective against IPD caused by the vaccine serotypes, and are now part of infant immunization programs in most European countries and elsewhere. While effective against IPD, the conjugate vaccines have much less efficacy against pneumococcal pneumonia which remains a major cause of childhood mortality globally.

AB - Pediatric vaccination against invasive pneumococcal disease (IPD) made a breakthrough in 2000 when a 7-valent pneumococcal conjugate vaccine was licensed. Subsequently, the spectrum was to introduce 10- and 13-valent conjugate vaccines PCV10 and PCV 13, which cover most of the IPD serotypes in children in developed countries. Those vaccines are highly effective against IPD caused by the vaccine serotypes, and are now part of infant immunization programs in most European countries and elsewhere. While effective against IPD, the conjugate vaccines have much less efficacy against pneumococcal pneumonia which remains a major cause of childhood mortality globally.

UR - http://www.scopus.com/inward/record.url?scp=85170187389&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-77173-7_21

DO - 10.1007/978-3-030-77173-7_21

M3 - Chapter

AN - SCOPUS:85170187389

SN - 9783030771720

SP - 223

EP - 247

BT - Pediatric Vaccines and Vaccinations

PB - Springer International Publishing

ER -

Pneumococcal Vaccines

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this